European shares in tentative rebound after sell-off, HSBC shines By Reuters

© Reuters. The German share price index DAX graph at the stock exchange in Frankfurt


By Julien Ponthus

LONDON (Reuters) – European shares, set for their worst monthly performance since August 2015, opened in positive territory on Monday in a tentative rebound from a sell-off which has depressed them to a level not seen since December 2016.

At 0957 GMT, the pan-European STOXX 600 () was up 1 percent with most bourses firmly in the black with U.S. stock futures turning positive despite worries about China’s slowing economy previously weighing on Asian shares.

“European markets enjoyed a stronger start to the week, despite a sell-off in China as investors digested the impact of a trade war with the US on industrial earnings”, said Russ Mould, investment director at AJ Bell.

The banking sector () was the best-performing one, up 1.8 percent with HSBC (L:) rising 4.5 percent after Europe’s biggest bank by assets posted a higher-than-expected 28 percent rise in third-quarter profit.

On the other hand, Spain’s state-controlled Bankia (MC:) was down 4.7 percent after posting lower than expected Q3 results.

Italian banks shone after rating agency S&P kept its credit rating two notches above non-investment grade for Italian sovereign bonds.

Banco BPM <.bami.mi> shares rose 3.3 percent, Ubi Banca (MI:) 3 percent and Unicredit (MI:) 2.5 percent.

Milan’s FTSE MIB () posted the best regional rise, up 1.2 percent while London’s rose 0.9 percent with investors waiting to learn more about Britain’s 2019 budget and what impact it might have on individual companies.

Frankfurt’s () accelerated its gains to 1.3 percent after a senior party source said German Chancellor Angela Merkel would not seek re-election as party chairwoman at a conference in early December.

The open of Paris CAC 40 () resumed after being delayed due to technical issues and was up 0.3 percent.

Another strong performing sector was healthcare (), up 1.7 percent with Novartis (S:) adding 1.9 percent.

The Swiss group and Pfizer Inc (NYSE:) PFE.N are teaming up to develop treatments for a liver disease many drug companies believe will become a hugely lucrative market, as it is tied to the obesity and diabetes epidemics.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *